[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Cancer Diagnostics Dealmaking in Biopharma Investigated in New CurrentPartnering Report Available at MarketPublishers.com

13 May 2014 • by Natalie Aster

LONDON – The majority of the cancer diagnostics deals are discovery and/or development stage whereby the licensee receives an option or a right to license the licensors cancer diagnostics technology. The cancer diagnostics partnering deals tend to be multicomponent, beginning from collaborative research and development, and commercialisation of results. Abbott, Eisai, Merck KGaA, Bristol-Myers Squibb, AstraZeneca, Gilead Sciences, Gilead Sciences, Amgen, Johnson & Johnson, Novartis, Bayer, Roche,   Astellas and Celgene are among the dominant healthcare companies that enter into the cancer diagnostics partnering deals.

A clear understanding of a prospective partner’s flexibility in negotiated deals terms provides critical insights into the partnership negotiation process regarding the outcomes expected to be achieved during the negotiation of terms.

New research study “Cancer Diagnostics Partnering Terms and Agreements” worked out by CurrentPartnering presents a clear understanding of the cancer diagnostics partnering terms and agreements, besides providing access to the cancer diagnostics partnering deals and agreements entered into by the world’s top healthcare companies.

A comprehensive summary of the prevailing trends in cancer diagnostics partnering deals; a complete set of contract documents; ranking of the cancer diagnostics deals by value and top-level data on upfronts, headlines, royalties and milestones by stage of development are provided in the cutting-edge research study. The insightful report discusses why and how the dominant healthcare companies enter cancer diagnostics partnering deals, and also includes above 900 links to online copies of present cancer diagnostics deals. Besides, the cutting-edge report gives answers to a range of questions concerning a prospective partner’s flexibility on a slew of important issues.

Report Details:

Cancer Diagnostics Partnering Terms and Agreements
Published: May, 2014
Pages: 1080
Price: US$ 2,995.00 

Other Healthcare Partnering Terms & Agreements Reports by CurrentPartnering:

More new research studies by the publisher can be found at CurrentPartnering page.


The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected] 

Analytics & News

Weekly Digest